Skin pain and discomfort in psoriasis: An exploratory study of symptom prevalence and characteristics

Acta Dermato-Venereologica

Volumn 90, Issue 1, 2010, Pages 39-45

  Ljosaa, Tone Marte ^a   Rustoen, Tone ^b   Mørk, Cato ^b   Stubhaug, Audun ^b   Miaskowski, Christine ^c   Paul, Steven M ^c   Wahl, Astrid K ^d  

^a UNIVERSITY OF SOUTH EASTERN NORWAY   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Discomfort; Pain; PASI; Psoriasis

Indexed keywords

ADULT; AGED; ARTICLE; BURNING SENSATION; CROSS-SECTIONAL STUDY; DEMOGRAPHY; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; QUESTIONNAIRE; RATING SCALE; SKIN DISCOMFORT; SKIN MANIFESTATION; SKIN PAIN; SKIN SENSITIVITY; SLEEP;

ADULT; AGED; CROSS-SECTIONAL STUDIES; DYSSOMNIAS; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; NORWAY; PAIN; PAIN MEASUREMENT; PREVALENCE; PRURITUS; PSORIASIS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 76349100286     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0764     Document Type: Article

References (54)

1. Dodd M, Janson S, Facione N, Faucett J, Froelicher ES, Humphreys J, et al. Advancing the science of symptom management. J Adv Nurs 2001; 33: 668-676.
2. Mork C, Wahl A, Mourn T. The Norwegian version of the dermatology life quality index: a study of validity and reliability in psoriatics. Acta Derm Venereol 2002; 82: 347-351.
3. Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol 2005; 152: 954-960.
4. Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 2003; 1: 53.
5. Sampogna F, Gisondi P, Melchi CF, Amerio P, Girolomoni G, Abeni D. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 2004; 151: 594-599.
6. Unaeze J, Nijsten T, Murphy A, Ravichandran C, Stern RS. Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. J Invest Dermatol 2006; 126: 1480-1489.
7. Merskey H, Bogduk N. Pain terms: a current list with definitions and notes on usage. In: Merskey H, Bogduk N, editor. Classification of chronic pain. Second edition. Seattle: IASP Press; 1994, p. 209-214.
8. Verhoeven EW, Kraaimaat FW, van de Kerkhof PC, van Weel C, Duller P, van der Valk PG, et al. Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice. Br J Dermatol 2007; 156: 1346-1349.
9. Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006; 154: 1161-1168.
10. Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006; 4: 71.
11. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999; 141: 1067-1075.
12. Sampogna F, Tabolli S, Soderfeldt B, Axtelius B, Aparo U, Abeni D. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol 2006; 154: 844-849.
13. Wahl A, Loge JH, Wiklund I, Hanestad BR. The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. J Am Acad Dermatol 2000; 43: 803-808.
14. Ware J. SF-36 Health survey manual and interpretation guide. Boston: New England Medical Center; 2000.
15. Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005; 153: 1192-1199.
16. Ortonne JP, Shear N, Shumack S, Henninger E. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatol 2005; 5: 13.
17. Sampogna F, Tabolli S, Mastroeni S, Di Pietro C, Fortes C, Abeni D. Quality of life impairment and psychological distress in elderly patients with psoriasis. Dermatology 2007; 215: 341-347.
18. Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol 2003; 49: 271-275.
19. Zhu X, Wang B, Zhao G, Gu J, Chen Z, Briantais P, et al. An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. J Eur Acad Dermatol Venereol 2007; 21: 466-472.
20. Robinson DJ, Collins P, Stringer MR, Vernon DI, Stables GI, Brown SB, et al. Improved response of plaque psoriasis after multiple treatments with topical 5-aminolaevulinic acid photodynamic therapy. Acta Derm Venereol 1999; 79: 451-455.
21. Zamirska A, Reich A, Berny-Moreno J, Salomon J, Szepietowski JC. Vulvar pruritus and burning sensation in women with psoriasis. Acta Derm Venereol 2008; 88: 132-135.
22. Chan MK, Chong LY. A prospective epidemiologic survey on the prevalence of foot disease in Hong Kong. J Am Podiatr Med Assoc 2002; 92: 450-456.
23. Haneke E. Achilles foot-screening project: background, objectives and design. J Eur Acad Dermatol Venereol 1999; 12: 6-9.
24. Leary MR, Rapp SR, Herbst KC, Exum ML, Feldman SR. Interpersonal concerns and psychological difficulties of psoriasis patients: effects of disease severity and fear of negative evaluation. Health Psychol 1998; 17: 530-536.
25. McKenna KE, Stern RS. The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. J Am Acad Dermatol 1997; 36: 388-394.
26. Nijsten T, Sampogna F, Stern RS, Abeni D. The reduced Impact of Psoriasis Questionnaire has good psychometric properties in Italian patients. Dermatology 2007; 215: 348-351.
27. Melzack R, Katz J. Pain assessment in adult patients. In: McMahon SB, Koltzenburg M, editor. Wall and Melzack's textbook of pain. 5th edn. Philadelphia: Elsevier/Churchill Livingstone,; 2006, p. 291-292.
28. Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat 2007; 18: 341-350.
29. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003; 49: 156-163.
30. Klepstad P, Loge JH, Borchgrevink PC, Mendoza TR, Cleeland CS, Kaasa S. The Norwegian brief pain inventory questionnaire: translation and validation in cancer pain patients. J Pain Symptom Manage 2002; 24: 517-525.
31. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994; 23: 129-138.
32. Zelman DC, Dukes E, Brandenburg N, Bostrom A, Gore M. Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. Pain 2005; 115: 29-36.
33. Jensen MP, Smith DG, Ehde DM, Robinsin LR. Pain site and the effects of amputation pain: further clarification of the meaning of mild, moderate, and severe pain. Pain 2001; 91: 317-322.
34. Krebs EE, Carey TS, Weinberger M. Accuracy of the pain numeric rating scale as a screening test in primary care. J Gen Intern Med 2007; 22: 1453-1458.
35. Hanley MA, Masedo A, Jensen MP, Cardenas D, Turner JA. Pain interference in persons with spinal cord injury: classification of mild, moderate, and severe pain. J Pain 2006; 7: 129-133.
36. Jensen MP, Gammaitoni AR, Olaleye DO, Oleka N, Nalamachu SR, Galer BS. The pain quality assessment scale: assessment of pain quality in carpal tunnel syndrome. J Pain 2006; 7: 823-832.
37. Acquadro C, Conway K, Girourdet C, Mear I. Linguistic Validation Manual for Patient-Reported Outcomes (PRO) Instruments. Lyon: Mapi Research Institute; 2004.
38. Paul SM, Zelman DC, Smith M, Miaskowski C. Categorizing the severity of cancer pain: further exploration of the establishment of cutpoints. Pain 2005; 113: 37-44.
39. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995; 61: 277-284.
40. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
41. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133: 1433-1440.
42. Dihle A, Bjolseth G, Helseth S. The gap between saying and doing in postoperative pain management. J Clin Nurs 2006; 15: 469-479.
43. Ho KY, Huh BK, White WD, Yeh CC, Miller EJ. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. Clin J Pain 2008; 24: 51-55.
44. Dworkin RH, Jensen MP, Gammaitoni AR, Olaleye DO, Galer BS. Symptom profiles differ in patients with neuropathic versus non-neuropathic pain. J Pain 2007; 8: 118-126.
45. Oaklander AL. Mechanisms of pain and itch caused by herpes zoster (shingles). J Pain 2008; 9: 10-18.
46. Devor M. Response of nerves to injury in relation to neuropathic pain. In: McMahon SB Koltzenburg M, editor. Wall and Melzack's textbook of pain. 5th edn. Philadelphia: Elsevier/Churchill Livingstone; 2006, p. 905.
47. Valeberg BT, Rustoen T, Bjordal K, Hanestad BR, Paul S, Miaskowski C. Self-reported prevalence, etiology, and characteristics of pain in oncology outpatients. Eur J Pain 2008; 12: 582-590.
48. Edrington JM, Paul S, Dodd M, West C, Facione N, Tripathy D, et al. No evidence for sex differences in the severity and treatment of cancer pain. J Pain Symptom Manage 2004; 28: 225-232.
49. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47: 123-128.
50. Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain 2007; 23: 490-496.
51. de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004; 9: 140-147.
52. Duffin KC, Wong B, Horn EJ, Krueger GG. Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. J Am Acad Dermatol 2009; 60: 604-608.
53. Holen JC, Lydersen S, Klepstad P, Loge JH, Kaasa S. The Brief Pain Inventory: pain's interference with functions is different in cancer pain compared with noncancer chronic pain. Clin J Pain 2008; 24: 219-225.
54. Dawson A, List T. Comparison of pain thresholds and pain tolerance levels between Middle Easterners and Swedes and between genders. J Oral Rehabil 2009; 36: 271-278.